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Relapsed or metastatic synovial sarcoma remains a signifi-
cant unmet medical need. NY-ESO-1 is an attractive target
for sarcoma, since it is expressed in approximately 70% of
synovial sarcomas but not on vital tissues. We generated
NY-ESOc259, a human-derived affinity-enhanced T-cell
receptor (TCR) that recognizes the NY-ESO-1– derived
SLLMWITQC peptide in complex with HLA-A*02. Adop-
tive transfer of autologous T cells expressing NY-ESOc259
was clinically tested in patients with metastatic synovial
cell sarcoma and melanoma whose tumor expressed NY-
ESO-1 protein at an intensity of ≥2+ and in 50% of cells
by immunohistochemistry; infusion followed precondi-
tioning with fludarabine and cyclophosphamide, and sys-
temic IL-2 support was given [1]. We subsequently
initiated a study in relapsed/metastatic synovial sarcoma,
with an updated T cell manufacturing method utilizing
anti-CD3/28 paramagnetic microbeads for simultaneous
activation and co-stimulation of T cells, and genetic modi-
fication with a lentivector (NCT01343043). No IL-2 sup-
port was given. Outcomes of this study were recently
presented[2]; clinical data demonstrate safety, objective
clinical responses in 50% of patients, and improved and
durable engineered T cell persistence. This study has
been extended to include two additional cohorts to eval-
uate the removal of fludarabine on tumor responses
(Cohort 3) and to evaluate responses in patients who
have antigen positive tumor below the current ≥2+ and
50% threshold (Cohort 2).
To better understand the lineage and functional charac-
teristics of the persisting engineered T cells, as well as to
understand the role of the starting material and manufac-
turing method in modifying the T cell phenotype and its
fate once in vivo, we performed multiparameter flow
analysis. Baseline and post infusion PBMCs, as well as
manufactured product, were analyzed to evaluate memory
and exhaustion markers (e.g. CD45RA, CCR7, PD-1),
polyfunctionality/cytotoxicity markers (e.g. IFN-g and
Granzyme B), and costimulatory markers (e.g. OX40,
ICOS, CD28). TCR expression was measured by pentamer.
Hierarchical cluster analysis was applied to identify trends
of expression of surface markers and their correlation with
final cell product profile, persistence and clinical response.
An update of Cohort 1 safety, efficacy and correlative
biomarker analyses, and a status update on Cohorts 2 and
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